Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio prospectivo, multicéntrico y no intervencionista para investigar la eficacia de REKOVELLE® para la estimulación ovárica en mujeres asiáticas en entornos del mundo real (PROFOUND)

29 de septiembre de 2026 actualizado por: Ferring Pharmaceuticals

Estudio prospectivo, multinacional y no intervencionista para investigar REKOVELLE para la estimulación ovárica: la eficacia, la seguridad y los patrones de uso para mujeres asiáticas en la práctica del mundo real

Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Actual)

1526

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Busan, Corea del Sur, 47245
        • Ferring Investigational Site
      • Seoul, Corea del Sur, 02586
        • Maria Fertility Hospital
    • Busan
      • Busan, Busan, Corea del Sur, 49241
        • Ferring Investigational Site
    • Daegu
      • Daegu, Daegu, Corea del Sur, 41910
        • Ferring Investigational Site
    • Seongnam
      • Seongnam-si, Seongnam, Corea del Sur, 13496
        • Ferring Investigational Site
      • Hiroshima, Japón, 7300035
        • Ferring Investigational Site
      • Hokkaido, Japón, 0600003
        • Ferring Investigational Site
      • Hyōgo, Japón, 6500021
        • Ferring Investigational Site
      • Osaka, Japón, 5300011
        • Ferring Investigational Site
      • Osaka, Japón, 5500015
        • Ferring Investigational Site
      • Saitama, Japón, 3540035
        • Ferring Investigational Site
    • Chiba
      • Chiba, Chiba, Japón, 2610023
        • Ferring Investigational Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japón, 8120013
        • Ferring Investigational Site
      • Kitakyushu, Fukuoka, Japón, 8070825
        • Ferring Investigational Site
    • Gunma
      • Takasaki, Gunma, Japón, 3700841
        • Ferring Investigational Site
    • Hiroshima
      • Hiroshima, Hiroshima, Japón, 7320822
        • Ferring Investigational Site
    • Japan
      • Bunkyō City, Japan, Japón, 1130033
        • Ferring Investigational Site
    • Tokyo
      • Tokyo, Tokyo, Japón, 1600023
        • Ferring Investigational Site
      • Bangkok, Tailandia, 10700
        • Ferring Investigational Site
    • Muang
      • Phitsanulok, Muang, Tailandia, 65000
        • Naresuan University Hospital
    • Ratchathewi
      • Bangkok, Ratchathewi, Tailandia, 10400
        • Ramathibodi Hospital
      • Taichung, Taiwán, 406
        • Ferring Investigational Site
      • Taipei, Taiwán, 100225
        • Ferring Investigational Site
      • Taipei, Taiwán, 110
        • Ferring Investigational Site
    • Tainan
      • Tainan, Tainan, Taiwán, 70403
        • Ferring Investigational Site
      • Tainan, Tainan, Taiwán, 71004
        • Ferring Investigational Site
    • Taoyuan
      • Taoyuan, Taoyuan, Taiwán, 333
        • Ferring Investigational Site
    • Hanoi
      • Hanoi, Hanoi, Vietnam, 100000
        • Ferring Investigational Site
    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
        • Ferring Investigational Site
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • Ferring Investigational Site
    • Huế
      • Huế, Huế, Vietnam, 49000
        • Ferring Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra de probabilidad

Población de estudio

Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.

Descripción

Inclusion Criteria:

  • Females aged 20 years or older at enrollment
  • Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
  • Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
  • Participating in an interventional clinical trial in which any medication treatment is mandated
  • Women with a contraindication for prescription of REKOVELLE treatment
  • Oocyte donors
  • Undergoing ovarian stimulation for fertility preservation

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
REKOVELLE

Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.

Individualised dosing regiment of REKOVELLE in routine clinical practice.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cumulative live birth rate
Periodo de tiempo: Up to 12 months

Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

Up to 12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The Luteinising hormone (LH) surge suppression protocol
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol.

Up to 22 days
Daily Dosage
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage.

Up to 22 days
Stimulation Duration
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration.

Up to 22 days
Total Dosage
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage.

Up to 22 days
Trigger Protocol
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the trigger protocol.

Up to 22 days
Luteal phase support protocol
Periodo de tiempo: Up to 22 days

Treatment pattern will be measured by analysing the luteal phase support protocol.

Up to 22 days
Number of oocytes retrieved
Periodo de tiempo: Up to 22 days

Number of oocytes retrieved at oocyte retrieval

Up to 22 days
Number of Metaphase II (MII) oocytes
Periodo de tiempo: Up to 22 days

Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI))

Up to 22 days
Number of embryos
Periodo de tiempo: Day 3 after oocyte retrieval

Number of embryos on Day 3 after oocyte retrieved

Day 3 after oocyte retrieval
Number of Blastocysts
Periodo de tiempo: Day 5 after oocyte retrieval

Number of Blastocysts on Day 5 after oocyte retrieved

Day 5 after oocyte retrieval
Number of embryos transferred
Periodo de tiempo: Up to 28 days

Embryos transferred in fresh and/or frozen transfer cycles

Up to 28 days
Number of blastocysts transferred
Periodo de tiempo: Up to 28 days

Blastocysts transferred in fresh and/or frozen transfer cycles

Up to 28 days
Implantation rate
Periodo de tiempo: Up to 28 days

Number of gestational sacs, embryos or blastocysts transferred

Up to 28 days
Positive human chorionic gonadotropin (hCG) rate
Periodo de tiempo: 11 to 15 days after transfer

Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer

11 to 15 days after transfer
Clinical Pregnancy rate
Periodo de tiempo: 4 to 5 weeks after transfer

Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer)

4 to 5 weeks after transfer
Vital Pregnancy
Periodo de tiempo: 4 to 5 weeks after transfer

Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer)

4 to 5 weeks after transfer
Ongoing pregnancy rate
Periodo de tiempo: 9 to 11 weeks after transfer

Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer)

9 to 11 weeks after transfer
Time to pregnancy
Periodo de tiempo: 4 to 5 weeks after transfer

Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy

4 to 5 weeks after transfer
Live birth rate
Periodo de tiempo: More than 20 weeks after transfer

Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle.

More than 20 weeks after transfer
Multiple pregnancy rate
Periodo de tiempo: 4 to 5 weeks after transfer

More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer

4 to 5 weeks after transfer
Spontaneous abortion rate
Periodo de tiempo: Up to 10-11 weeks after transfer

Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound

Up to 10-11 weeks after transfer
Ectopic pregnancy rate
Periodo de tiempo: Up to 10-11 weeks after transfer

Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

Up to 10-11 weeks after transfer
Estradiol Hormone levels
Periodo de tiempo: Up to 20 days

Estradiol hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Progesterone Hormone levels
Periodo de tiempo: Up to 20 days

Progesterone hormone levels before stimulation and at the end of stimulation day

Up to 20 days
Cycle cancellation rate and the reason for cycle cancellation
Periodo de tiempo: Up to 28 days

Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason)

Up to 28 days
Transfer cancellation rate and the reason for transfer cancellation
Periodo de tiempo: Up to 28 days

Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation).

Up to 28 days
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Frequency and severity of ADRs and SAEs as defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.

Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer)

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Periodo de tiempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Number of subjects with mild / moderate / severe OHSS, defined by the investigator

During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Global Clinical Compliance, Ferring Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de agosto de 2024

Finalización primaria (Estimado)

1 de mayo de 2027

Finalización del estudio (Estimado)

1 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

6 de agosto de 2024

Primero enviado que cumplió con los criterios de control de calidad

16 de agosto de 2024

Publicado por primera vez (Actual)

20 de agosto de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 000430

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir